A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Toxicology and Applied Pharmacology (Impact Factor: 3.63). 12/2011; 258(2):268-74. DOI: 10.1016/j.taap.2011.11.006
Source: PubMed

ABSTRACT Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor and serves as a key regulator to maintain health of the liver and intestine. Bile acids are endogenous ligands of FXR, and there are increasing efforts to identify FXR modulators to serve as biological probes and/or pharmaceutical agents. Natural FXR ligands isolated from plants may serve as models to synthesize novel FXR modulators. In this study, we demonstrated that epigallocatechin-3-gallate (EGCG), a major tea catechin, specifically and dose-dependently activates FXR. In addition, EGCG induced FXR target gene expression in vitro. Surprisingly, in a co-activator (SRC2) recruitment assay, we found that EGCG does not recruit SRC2 to FXR, but it dose-dependently inhibits recruitment of SRC2 to FXR (IC(50), 1μM) by GW6064, which is a potent FXR synthetic ligand. In addition, EGCG suppressed FXR target gene expression induced by either GW4064 or chenodeoxycholic acid in vitro. Furthermore, wild-type and FXR knockout mice treated with an acute dose of EGCG had induced mRNA expression in a subset of FXR target genes in the intestine but not in the liver. In conclusion, EGCG is a unique modulator of FXR in the intestine and may serve as an important model for future development of FXR modulators.

Download full-text


Available from: Grace Guo, Apr 25, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the contents of indigo's bioactive compounds, its antioxidant and anticancer activities in acetone, hexane and DMSO extracts and to compare the overall bioactivity with another more used medicinal plant named prolipid. It was found that the contents of the bioactive compounds in the studied extracts from different parts of indigo plant varied (P < 0.05): the significantly highest content of polyphenols and flavonoids was in DMSO extract of prolipid, flavanols – in acetone extract of brown seeds (P < 0.05 in both cases) and tannins – in DMSO extract of green leaves, but not significantly (P > 0.05). Also the level of antioxidant activity was different: the highest antioxidant activity of all studied samples was in prolipid: according to ABTS, FRAP and CUPRAC tests in DMSO extract (P < 0.05 in all 3 cases), and only in acetone extract according to DPPH was not significant (P > 0.05). The correlations between polyphenol compounds and the antioxidant activities were relatively high. DPPH kinetic measurements were used to compare and distinguish the antiradical activity among indigo extracts by multivariate analysis. The FT-IR spectroscopy evaluated the presence of polyphenols. The interaction between DMSO polyphenol extracts of indigo plant and BSA showed that indigo has a strong ability as other medicinal plants such as prolipid to quench the intrinsic fluorescence of BSA by forming complexes and was measured by 3-dimensional fluorescence (3D-FL). The highest anticancer activity was in prolipid in concentrations of 800 μg/mL against Calu-6, following by indigo brown leaves. In conclusion, organic extracts of indigo brown leaves were analyzed for their antioxidant and anticancer activities and compared with prolipid, using polyphenols composition, antioxidant activities and fluorescence properties. The indigo ability to quench the intrinsic fluorescence of BSA, relatively high content of phenolic compounds and anticancer properties can be used as medicinal plant.
    Industrial Crops and Products 03/2013; 42(1):429–439. DOI:10.1016/j.indcrop.2012.06.029 · 2.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the studyDiets containing high cholesterol levels led to atherosclerosis damage in the livers and hearts of rats. The aim of this study was to investigate the possible positive effects of durian fruit against high-cholesterol diets.
    European Journal of Integrative Medicine 09/2011; 3(3). DOI:10.1016/j.eujim.2011.08.005 · 0.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The beneficial effect of the major green tea catechin, epigallocatechin gallate (EGCG), on cholesterol homeostasis has been studied mainly in relation to the intestinal absorption of cholesterol; however, how EGCG affects cholesterol metabolism in the liver is not entirely known. The present study investigated the effect of EGCG on liver cholesterol metabolism in healthy and ethinylestradiol-treated rats. EGCG treatment reduced plasma total cholesterol in ethinylestradiol-treated animals and very low density lipoprotein cholesterol in both groups receiving EGCG. In healthy rats, despite the decrease in bile flow, EGCG markedly enhanced biliary secretion of cholesterol and phospholipids. These changes were correlated with increased expression of ATP-binding cassette transporter G5 and G8 and scavenger receptor class B type 1, and decreased expression of acyl-CoA:cholesterol acyltransferase. Ethinylestradiol treatment caused marked hepatic cholesterol accumulation with a concomitant liver weight increase and plasma cholesterol reduction. In ethinylestradiol-treated rats, EGCG co-administration attenuated the increase in liver cholesterol and liver weight. Furthermore, EGCG blunted induction of acyl-CoA:cholesterol acyltransferase and raised reduced levels of ATP-binding cassette transporter G5 and G8 and 3-hydroxy-3-methyl-glutaryl-CoA reductase in ethinylestradiol-treated rats. In conclusion, this study has demonstrated for the first time the ability of EGCG to enhance biliary cholesterol secretion and to attenuate ethinylestradiol-induced liver cholesterol accumulation. Changes in the expression of relevant enzymes and transporters suggest evidence of another mechanism that may contribute to the overall effect of EGCG on cholesterol metabolism and imply new physiological consequences of this widely used compound.
    European journal of pharmacology 07/2012; 691(1-3):38-45. DOI:10.1016/j.ejphar.2012.06.034 · 2.68 Impact Factor
Show more